NEWARK,
Calif., Dec. 21, 2022 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company")
today announced that Dinesh V.
Patel, Ph.D., President and Chief Executive Officer, will
offer a corporate presentation and host one-on-one meetings with
investors at the 41st Annual J.P. Morgan Healthcare
Conference, taking place January 9-12
in San Francisco, California.
Presentation Details:
Date: Wednesday, January 11, 2023
Time: 7:30 a.m. PT
Location: Westin St. Francis, 335 Powell Street, San Francisco.
A webcast of the event will be available on the Investors
section of the Protagonist Therapeutics website at
http://investors.protagonist-inc.com/.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with
peptide-based new chemical entities rusfertide and PN-235 in
advanced stages of clinical development, both derived from the
Company's proprietary technology platform. Rusfertide, a mimetic of
the natural hormone hepcidin, is the Company's lead drug candidate
currently in a global Phase 3 stage of development. The Phase 3
VERIFY and Phase 2 REVIVE studies of rusfertide in polycythemia
vera are ongoing. Protagonist retains all worldwide development and
commercialization rights to rusfertide.
Protagonist has partnered with Janssen Biotech, Inc. on the
development of oral IL-23 receptor antagonist PN-235 (JNJ-77242113)
for all clinical indications, including psoriasis and inflammatory
bowel diseases. PN-235 is currently in multiple clinical studies
including a Phase 2b study in
moderate-to-severe plaque psoriasis, led by Janssen.
Protagonist is headquartered in Newark, California. For more information on
Protagonist, please visit the Company's website at
www.protagonist-inc.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-41st-annual-jp-morgan-healthcare-conference-301708553.html
SOURCE Protagonist Therapeutics, Inc.